VolitionRx Limited (VNRX) Investor Relations Documents

VolitionRx Limited (VNRX) investor relations documents from the company's IR site: 40 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-26Press releaseVolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
2026-08-26Press releaseVolition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis
2026-08-13Press releaseVolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update
2026-08-12Press releaseVolition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
2026-08-11Press releaseVolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update
2026-08-05Press releaseVolition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
2026-07-30Press releaseVolition Advances Nu.Q® NETs Platform Towards Commercialization
2026-07-07Press releaseVolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test
2026-06-17Press releaseVolitionRx Announces Collaboration with Sysmex
2026-06-07Press releaseVolitionRx Announces Pricing of $4.6 Million Public Offering
2026-06-03Press releaseVolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
2026-05-27Press releaseVolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
Press releaseRead Press Release
2026-05-14Press releasePDF
Press releaseRead Press Release
Press releaseVolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update
Press releaseVolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update
Press releaseVolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update
Press releaseVolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update
Press releaseVolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update
Press releaseVolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update
Press releaseVolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update
Press releaseVolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update
2025-03-31Press releaseVolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update
2025-03-31Press releaseEarnings Release FY 2024 PDF
2024-11-14Press releaseVolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update
2024-11-14Press releaseEarnings Release Q3 2024 PDF
2024-11-08Press releaseVolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update
2024-08-14Press releaseEarnings Release HTML
2024-08-14Press releaseEarnings Release Q2 2024 PDF
2024-05-13Press releaseEarnings Release HTML
2024-03-25Press releaseEarnings Release HTML
2023-11-14Press releaseEarnings Release HTML
2023-08-14Press releaseEarnings Release HTML
2023-05-10Press releaseEarnings Release HTML
2023-03-15Press releaseEarnings Release HTML
2022-11-14Press releaseEarnings Release HTML
2022-08-10Press releaseEarnings Release HTML
2022-05-11Press releaseEarnings Release HTML
2022-03-30Press releaseEarnings Release HTML

VNRX overview · VNRX earnings · VNRX financials · VNRX KPIs · VNRX documents · VNRX ownership · VNRX peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.